The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Open accessAbstract
The SHARP study in 2007 [1] and the Asia Pacific study in 2008 [2] led to the worldwide approval of sorafenib as the standard therapy for unresectable hepatocellular carcinoma (HCC). However, clinical trials investigating sunitinib [3] , brivanib [4] , and linifanib [5] as first-line treatments, with sorafenib as a control arm, failed to meet their primary endpoint of improving overall survival (OS). In addition, global phase III studies investigating secondline therapy with brivanib [6] , everolimus [7] , and ramucirumab [8] , and a regional trial investigating S-1 (tegafur/gimeracil/oteracil) in Japan, were unsuccessful ( Table 1 ). Thus, sorafenib was the only systemic therapeutic agent available for HCC, and for some time no options were available for patients with progressive disease or those intolerant to sorafenib. However, between June 2016 and January 2017, promising results of global phase III studies were reported. The results of a trial of regorafenib were reported at a conference [9] and in a journal [10] , and results with lenvatinib were reported in a press release [11] , indicating the arrival of a new era of liver cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Self-citationZhu, A. X., Park, J. O., Ryoo, B.-Y., Yen, C.-J., Poon, R., Pastorelli, D., Blanc, J.-F., Chung, H. C., Baron, A. D., Pfiffer, T. E. F., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00050-9 · Cited by 846
Self-citationCheng, A.-L., Kang, Y.-K., Lin, D.-Y., Park, J.-W., Kudo, M., Qin, S., Chung, H.-C., Song, X., Xu, J., Poggi, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8372 · Cited by 777
Self-citationJohnson, P. J., Qin, S., Park, J.-W., Poon, R. T. P., Raoul, J.-L., Philip, P. A., Hsu, C.-H., Hu, T.-H., Heo, J., Xu, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4410 · Cited by 772
Self-citationCainap, C., Qin, S., Huang, W.-T., Chung, I. J., Pan, H., Cheng, Y., Kudo, M., Kang, Y.-K., Chen, P.-J., Toh, H.-C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3298 · Cited by 629
Self-citationLlovet, J. M., Decaens, T., Raoul, J.-L., Boucher, E., Kudo, M., Chang, C., Kang, Y.-K., Assenat, E., Lim, H.-Y., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3009 · Cited by 596
Self-citationKudo, M., Imanaka, K., Chida, N., Nakachi, K., Tak, W.-Y., Takayama, T., Yoon, J.-H., Hori, T., Kumada, H., Hayashi, N., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.007 · Cited by 570
Self-citationZhu, A. X., Kudo, M., Assenat, E., Cattan, S., Kang, Y.-K., Lim, H. Y., Poon, R. T. P., Blanc, J.-F., Vogel, A., Chen, C.-L., et al. (2014) · JAMA · doi:10.1001/jama.2014.7189 · Cited by 568
Self-citation
Cited by
Items 101–200 of 214
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
Self-citationHo, W. J., Zhu, Q., Durham, J., Popovic, A., Xavier, S., Leatherman, J., Mohan, A., Mo, G., Zhang, S., Gross, N., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00234-4 · Cited by 360
Comprehensive analysis of spatial architecture in primary liver cancer
Wu, R., Guo, W., Qiu, X., Wang, S., Sui, C., Lian, Q., Wu, J., Shan, Y., Yang, Z., Yang, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg3750 · Cited by 369
Saito, T., Ichimura, Y., Taguchi, K., Suzuki, T., Mizushima, T., Takagi, K., Hirose, Y., Nagahashi, M., Iso, T., Fukutomi, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12030 · Cited by 362
Liver organoids: from basic research to therapeutic applications
Prior, N., Inacio, P., & Huch, M. (2019) · Gut · doi:10.1136/gutjnl-2019-319256 · Cited by 356
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00754-7 · Cited by 354
Terpenoids as potential chemopreventive and therapeutic agents in liver cancer
Thoppil, R. J. (2011) · World Journal of Hepatology · doi:10.4254/wjh.v3.i9.228 · Cited by 353
TGF-β and the Tissue Microenvironment: Relevance in Fibrosis and Cancer
Caja, L., Dituri, F., Mancarella, S., Caballero-Diaz, D., Moustakas, A., Giannelli, G., & Fabregat, I. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051294 · Cited by 351
NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017
Benson, A. B., D'Angelica, M. I., Abbott, D. E., Abrams, T. A., Alberts, S. R., Anaya, D. A., Are, C., Brown, D. B., Chang, D. T., Covey, A. M., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0059 · Cited by 345
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors
Méndez-Blanco, C., Fondevila, F., García-Palomo, A., González-Gallego, J., & Mauriz, J. L. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0159-1 · Cited by 339
The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review
Pinter, M., Jain, R. K., & Duda, D. G. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.3381 · Cited by 339
Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma
Chang, Y., Jeong, S. W., Young Jang, J., & Jae Kim, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218165 · Cited by 336
Hiraoka, A., Michitaka, K., Kumada, T., Izumi, N., Kadoya, M., Kokudo, N., Kubo, S., Matsuyama, Y., Nakashima, O., Sakamoto, M., et al. (2017) · Liver Cancer · doi:10.1159/000479984 · Cited by 331
Self-citationAstrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression
Yoo, B. K., Emdad, L., Su, Z.-Z., Villanueva, A., Chiang, D. Y., Mukhopadhyay, N. D., Mills, A. S., Waxman, S., Fisher, R. A., Llovet, J. M., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36460 · Cited by 328
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
Moon, H., & Ro, S. W. (2021) · Cancers · doi:10.3390/cancers13123026 · Cited by 326
Pinyol, R., Montal, R., Bassaganyas, L., Sia, D., Takayama, T., Chau, G.-Y., Mazzaferro, V., Roayaie, S., Lee, H. C., Kokudo, N., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316408 · Cited by 326
Zhang, Q., Lou, Y., Yang, J., Wang, J., Feng, J., Zhao, Y., Wang, L., Huang, X., Fu, Q., Ye, M., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318912 · Cited by 326
Control of the Immune Response by Pro-Angiogenic Factors
Voron, T., Marcheteau, E., Pernot, S., Colussi, O., Tartour, E., Taieb, J., & Terme, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00070 · Cited by 325
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Qin, S., Li, A., Yi, M., Yu, S., Zhang, M., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0718-5 · Cited by 324
A targetable LIFR−NF-κB−LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis
Yao, F., Deng, Y., Zhao, Y., Mei, Y., Zhang, Y., Liu, X., Martinez, C., Su, X., Rosato, R. R., Teng, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27452-9 · Cited by 322
Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma
Johnson, P., Zhou, Q., Dao, D. Y., & Lo, Y. M. D. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00620-y · Cited by 320
Roessler, S., Long, E. L., Budhu, A., Chen, Y., Zhao, X., Ji, J., Walker, R., Jia, H., Ye, Q., Qin, L., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.039 · Cited by 319
Notch Signaling Is Activated in Human Hepatocellular Carcinoma and Induces Tumor Formation in Mice
Villanueva, A., Alsinet, C., Yanger, K., Hoshida, Y., Zong, Y., Toffanin, S., Rodriguez–Carunchio, L., Solé, M., Thung, S., Stanger, B. Z., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.09.002 · Cited by 318
Lenvatinib: A Review in Hepatocellular Carcinoma
Al-Salama, Z. T., Syed, Y. Y., & Scott, L. J. (2019) · Drugs · doi:10.1007/s40265-019-01116-x · Cited by 318
Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review
Desai, A., Sandhu, S., Lai, J.-P., & Sandhu, D. S. (2019) · World Journal of Hepatology · doi:10.4254/wjh.v11.i1.1 · Cited by 317
Targeting angiogenesis in oncology, ophthalmology and beyond
Cao, Y., Langer, R., & Ferrara, N. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00671-z · Cited by 315
Kudo, M., Han, K.-H., Ye, S.-L., Zhou, J., Huang, Y.-H., Lin, S.-M., Wang, C.-K., Ikeda, M., Chan, S. L., Choo, S. P., et al. (2020) · Liver Cancer · doi:10.1159/000507370 · Cited by 314
Self-citationTargeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment
Vilchez, V. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.823 · Cited by 312
Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells
Ruf, B., Heinrich, B., & Greten, T. F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00572-w · Cited by 312
Positron Emission Tomography (PET) in Oncology
Gallamini, A., Zwarthoed, C., & Borra, A. (2014) · Cancers · doi:10.3390/cancers6041821 · Cited by 312
Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma
Dimri, M., & Satyanarayana, A. (2020) · Cancers · doi:10.3390/cancers12020491 · Cited by 311
Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements
Hoshida, Y., Toffanin, S., Lachenmayer, A., Villanueva, A., Minguez, B., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247131 · Cited by 310
Kudo, M., Ueshima, K., Chan, S., Minami, T., Chishina, H., Aoki, T., Takita, M., Hagiwara, S., Minami, Y., Ida, H., et al. (2019) · Cancers · doi:10.3390/cancers11081084 · Cited by 309
Self-citationSorafenib: A Review in Hepatocellular Carcinoma
Keating, G. M. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0484-7 · Cited by 308
Cárdenes, H. R., Price, T. R., Perkins, S. M., Maluccio, M., Kwo, P., Breen, T. E., Henderson, M. A., Schefter, T. E., Tudor, K., Deluca, J., et al. (2010) · Clinical and Translational Oncology · doi:10.1007/s12094-010-0492-x · Cited by 307
Hepatocellular carcinoma: old friends and new tricks
Kim, E., & Viatour, P. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00527-1 · Cited by 307
Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma
Chen, C., Wang, Z., Ding, Y., & Qin, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133308 · Cited by 305
Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review
Daher, S., Massarwa, M., Benson, A. A., & Khoury, T. (2018) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00031 · Cited by 304
A comprehensive review of protein kinase inhibitors for cancer therapy
Kannaiyan, R., & Mahadevan, D. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1527688 · Cited by 302
Targeted and Immune-Based Therapies for Hepatocellular Carcinoma
Greten, T. F., Lai, C. W., Li, G., & Staveley-O’Carroll, K. F. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.09.051 · Cited by 294
Zhu, H.-D., Li, H.-L., Huang, M.-S., Yang, W.-Z., Yin, G.-W., Zhong, B.-Y., Sun, J.-H., Jin, Z.-C., Chen, J.-J., Ge, N.-J., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01235-0 · Cited by 294
Bollard, J., Miguela, V., Ruiz de Galarreta, M., Venkatesh, A., Bian, C. B., Roberto, M. P., Tovar, V., Sia, D., Molina-Sánchez, P., Nguyen, C. B., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312268 · Cited by 291
Cardiovascular Complications of Cancer Therapy
Chang, H.-M., Okwuosa, T. M., Scarabelli, T., Moudgil, R., & Yeh, E. T. H. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.1095 · Cited by 290
Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization.
Okamoto, K., Ikemori-Kawada, M., Jestel, A., von König, K., Funahashi, Y., Matsushima, T., Tsuruoka, A., Inoue, A., & Matsui, J. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500394m · Cited by 285
Liver cancer: Approaching a personalized care
Bruix, J., Han, K.-H., Gores, G., Llovet, J. M., & Mazzaferro, V. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.007 · Cited by 284
Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
Sun, E. J., Wankell, M., Palamuthusingam, P., McFarlane, C., & Hebbard, L. (2021) · Biomedicines · doi:10.3390/biomedicines9111639 · Cited by 281
Recent advances in hepatocellular carcinoma therapy
Dutta, R., & Mahato, R. I. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.010 · Cited by 280
Kanda, T., Goto, T., Hirotsu, Y., Moriyama, M., & Omata, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061358 · Cited by 280
Zhang, Z., Zeng, X., Wu, Y., Liu, Y., Zhang, X., & Song, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.925618 · Cited by 275
Yu, S. J. (2016) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2016.22.1.7 · Cited by 273
Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight
Lohitesh, K., Chowdhury, R., & Mukherjee, S. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0538-7 · Cited by 270
Matsuki, M., Hoshi, T., Yamamoto, Y., Ikemori‐Kawada, M., Minoshima, Y., Funahashi, Y., & Matsui, J. (2018) · Cancer Medicine · doi:10.1002/cam4.1517 · Cited by 266
Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies
Alqahtani, A., Khan, Z., Alloghbi, A., S. Said Ahmed, T., Ashraf, M., & M. Hammouda, D. (2019) · Medicina · doi:10.3390/medicina55090526 · Cited by 265
Serper, M., Taddei, T. H., Mehta, R., D’Addeo, K., Dai, F., Aytaman, A., Baytarian, M., Fox, R., Hunt, K., Goldberg, D. S., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.02.040 · Cited by 265
Wang, Y., Wang, J., Li, X., Xiong, X., Wang, J., Zhou, Z., Zhu, X., Gu, Y., Dominissini, D., He, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26718-6 · Cited by 265
Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma
Bouattour, M., Raymond, E., Qin, S., Cheng, A., Stammberger, U., Locatelli, G., & Faivre, S. (2018) · Hepatology · doi:10.1002/hep.29496 · Cited by 257
Hepatocellular Carcinoma: Etiology and Current and Future Drugs
Jindal, A., Thadi, A., & Shailubhai, K. (2019) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2019.01.004 · Cited by 257
El‐Kenawi, A. E., & El‐Remessy, A. B. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12344 · Cited by 253
Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC
Pinyol, R., Sia, D., & Llovet, J. M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3778 · Cited by 249
YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression
Fitamant, J., Kottakis, F., Benhamouche, S., Tian, H. S., Chuvin, N., Parachoniak, C. A., Nagle, J. M., Perera, R. M., Lapouge, M., Deshpande, V., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.027 · Cited by 248
Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics
Abdalla, A. M. E., Xiao, L., Ullah, M. W., Yu, M., Ouyang, C., & Yang, G. (2018) · Theranostics · doi:10.7150/thno.21674 · Cited by 240
Anti-VEGF therapies in the clinic
Meadows, K. L., & Hurwitz, H. I. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006577 · Cited by 237
Biomarkers for immunotherapy of hepatocellular carcinoma
Greten, T. F., Villanueva, A., Korangy, F., Ruf, B., Yarchoan, M., Ma, L., Ruppin, E., & Wang, X. W. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00816-4 · Cited by 227
Cancer combination therapies by angiogenesis inhibitors; a comprehensive review
Ansari, M. J., Bokov, D., Markov, A., Jalil, A. T., Shalaby, M. N., Suksatan, W., Chupradit, S., AL-Ghamdi, H. S., Shomali, N., Zamani, A., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00838-y · Cited by 197
Kung-Chun Chiu, D., Pui-Wah Tse, A., Law, C.-T., Ming-Jing Xu, I., Lee, D., Chen, M., Kit-Ho Lai, R., Wai-Hin Yuen, V., Wing-Sum Cheu, J., Wai-Hung Ho, D., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-2155-3 · Cited by 192
Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis
Matsuda, M., & Seki, E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1708876 · Cited by 189
A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy
Kong, D.-H., Kim, M., Jang, J., Na, H.-J., & Lee, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081786 · Cited by 161
Cappuyns, S., Corbett, V., Yarchoan, M., Finn, R. S., & Llovet, J. M. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.2677 · Cited by 167
Adebayo Michael, A. O., Ko, S., Tao, J., Moghe, A., Yang, H., Xu, M., Russell, J. O., Pradhan-Sundd, T., Liu, S., Singh, S., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.002 · Cited by 155
Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma
Chen, B., Garmire, L., Calvisi, D. F., Chua, M.-S., Kelley, R. K., & Chen, X. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0240-9 · Cited by 154
Extracellular Matrix Cues Regulate Mechanosensing and Mechanotransduction of Cancer Cells
Mierke, C. T. (2024) · Cells · doi:10.3390/cells13010096 · Cited by 146
Wang, K., Xiang, Y.-J., Yu, H.-M., Cheng, Y.-Q., Liu, Z.-H., Qin, Y.-Y., Shi, J., Guo, W.-X., Lu, C.-D., Zheng, Y.-X., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02786-7 · Cited by 142
Zhang, W., Tong, S., Hu, B., Wan, T., Tang, H., Zhao, F., Jiao, T., Li, J., Zhang, Z., Cai, J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007366 · Cited by 136
Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma
Shrestha, R., Prithviraj, P., Anaka, M., Bridle, K. R., Crawford, D. H. G., Dhungel, B., Steel, J. C., & Jayachandran, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00269 · Cited by 132
Lai, S.-C., Su, Y.-T., Chi, C.-C., Kuo, Y.-C., Lee, K.-F., Wu, Y.-C., Lan, P.-C., Yang, M.-H., Chang, T.-S., & Huang, Y.-H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1442-2 · Cited by 128
Yeo, W., Chan, S. L., Mo, F. K., Chu, C. M., Hui, J. W., Tong, J. H., Chan, A. W., Koh, J., Hui, E. P., Loong, H., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1334-6 · Cited by 125
Ko, S.-F., Yip, H.-K., Zhen, Y.-Y., Lee, C.-C., Lee, C.-C., Huang, C.-C., Ng, S.-H., & Lin, J.-W. (2015) · Stem Cells International · doi:10.1155/2015/853506 · Cited by 125
The Role of Sinusoidal Endothelial Cells in the Axis of Inflammation and Cancer Within the Liver
Wilkinson, A. L., Qurashi, M., & Shetty, S. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00990 · Cited by 121
Doleschel, D., Hoff, S., Koletnik, S., Rix, A., Zopf, D., Kiessling, F., & Lederle, W. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02043-0 · Cited by 114
Obesity early in adulthood increases risk but does not affect outcomes of hepatocellular carcinoma
Hassan, M. M., Abdel-Wahab, R., Kaseb, A., Shalaby, A., Phan, A. T., El-Serag, H. B., Hawk, E., Morris, J., Singh Raghav, K. P., Lee, J.-S., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.044 · Cited by 110
Lee, P.-C., Chao, Y., Chen, M.-H., Lan, K.-H., Lee, C.-J., Lee, I.-C., Chen, S.-C., Hou, M.-C., & Huang, Y.-H. (2020) · Cancers · doi:10.3390/cancers12010182 · Cited by 105
Activating CAR and β-catenin induces uncontrolled liver growth and tumorigenesis
Dong, B., Lee, J.-S., Park, Y.-Y., Yang, F., Xu, G., Huang, W., Finegold, M. J., & Moore, D. D. (2015) · Nature Communications · doi:10.1038/ncomms6944 · Cited by 97
Kim, Y.-S., Lee, Y.-M., Oh, T.-I., Shin, D. H., Kim, G.-H., Kan, S.-Y., Kang, H., Kim, J. H., Kim, B. M., Yim, W. J., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103127 · Cited by 97
Liu, Y., Ye, X., Zhang, J.-B., Ouyang, H., Shen, Z., Wu, Y., Wang, W., Wu, J., Tao, S., Yang, X., et al. (2015) · Oncogene · doi:10.1038/onc.2015.7 · Cited by 93
AbouAitah, K., Swiderska-Sroda, A., Farghali, A. A., Wojnarowicz, J., Stefanek, A., Gierlotka, S., Opalinska, A., Allayeh, A. K., Ciach, T., & Lojkowski, W. (2018) · Oncotarget · doi:10.18632/oncotarget.25470 · Cited by 83
Zhang, X.-Y., Li, S.-S., Gu, Y.-R., Xiao, L.-X., Ma, X.-Y., Chen, X.-R., Wang, J.-L., Liao, C.-H., Lin, B.-L., Huang, Y.-H., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02030-x · Cited by 80
Zhang, R., Ma, M., Lin, X.-H., Liu, H.-H., Chen, J., Chen, J., Gao, D.-M., Cui, J.-F., Ren, Z.-G., & Chen, R.-X. (2018) · BMC Cancer · doi:10.1186/s12885-018-4820-9 · Cited by 68
Hsu, M.-C., Pan, M.-R., & Hung, W.-C. (2019) · Cells · doi:10.3390/cells8030270 · Cited by 67
Jansen, R. W., van Amstel, P., Martens, R. M., Kooi, I. E., Wesseling, P., de Langen, A. J., Menke-Van der Houven van Oordt, C. W., Jansen, B. H. E., Moll, A. C., Dorsman, J. C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24893 · Cited by 63
Hypoxia-inducible factor orchestrates adenosine metabolism to promote liver cancer development
Cheu, J. W.-S., Chiu, D. K.-C., Kwan, K. K.-L., Yang, C., Yuen, V. W.-H., Goh, C. C., Chui, N. N.-Q., Shen, W., Law, C.-T., Li, Q., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade5111 · Cited by 65
STAT3 in hepatocellular carcinoma: new perspectives
Svinka, J., Mikulits, W., & Eferl, R. (2014) · Hepatic Oncology · doi:10.2217/hep.13.7 · Cited by 63
Targeting SphK2 reverses acquired resistance of Regorafenib in hepatocellular carcinoma
Shi, W., Zhang, S., Ma, D., Yan, D., Zhang, G., Cao, Y., Wang, Z., Wu, J., & Jiang, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00694 · Cited by 61
Jeong, W., Doroshow, J. H., & Kummar, S. (2013) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2013.06.001 · Cited by 59
Ikeda, M., Morimoto, M., Tajimi, M., Inoue, K., Benhadji, K. A., Lahn, M. M. F., & Sakai, D. (2019) · Investigational New Drugs · doi:10.1007/s10637-018-0636-3 · Cited by 46
RBM45 reprograms lipid metabolism promoting hepatocellular carcinoma via Rictor and ACSL1/ACSL4
Wang, C., Chen, Z., Yi, Y., Ding, Y., Xu, F., Kang, H., Lin, K., Shu, X., Zhong, Z., Zhang, Z., et al. (2024) · Oncogene · doi:10.1038/s41388-023-02902-4 · Cited by 42
Ding, J., Zhou, X.-T., Zou, H.-Y., & Wu, J. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.34 · Cited by 42
Wu, J., Contratto, M., Shanbhogue, K. P., Manji, G. A., O’Neil, B. H., Noonan, A., Tudor, R., & Lee, R. (2019) · World Journal of Clinical Oncology · doi:10.5306/wjco.v10.i3.149 · Cited by 41
Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC
Boslem, E., Reibe, S., Carlessi, R., Smeuninx, B., Tegegne, S., Egan, C. L., McLennan, E., Terry, L. V., Nobis, M., Mu, A., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh0831 · Cited by 39
Metadata
- Authors
- Kudo, M.
- Venue
- Liver Cancer
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 6
- Issue
- 3
- Pages
- 177-184
- ISSN
- 2235-1795
- 1664-5553
- OpenAlex
- W2591655368
- Cited by
- 5,936
- References
- 27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.